Production of Recombinant Biopharmaceuticals in Chlamydomonas reinhardtii
Cesar Andres Diaz Arias, Caroline Frere Martiniuc de Oliveira, João Vitor Dutra Molino, Livia Seno Ferreira‐Camargo, Marcelo Chuei Matsudo, João Carlos Monteiro de Carvalho
Abstract
This review aimed to present Chlamydomonas reinhardtii as an alternative for heterologous protein production, especially for biopharmaceuticals, and its general characteristics when compared with other expression systems. The need to produce heterologous proteins for industrial interest, therapeutic ends, and diagnostic kits has led to the development of recombinant microalgal technology. This technology presents some interesting features, such as rapid growth and low transgene dispersion compared to plants, the ability to fold complex proteins compared to bacteria, and low production costs compared to other expression systems, such as yeast and mammalian cells. Overall, C. reinhardtii heterologous protein expression is coming of age with several research groups focused on developing an optimal producer strain.